Clinical trials: Age Related Maculopathy
Dry Age Related Macular Degeneration
Dry Age-Related Macular Degeneration (AMD) Treatment With Rheopheresis Trial
Purpose is to evaluate Rheopheresis for the treatment of patients with high-risk dry age-related macular degeneration and no therapeutic alternative.
- Trial name
- ART (NCT00751361)
- Testing
- Rheopheresis / double filtration plasmapheresis
- Where
- Germany
- Volunteers
- 52 people
- Sponsor
- Apheresis Research Institute
Periodontitis
Connection Between Periodontitis and Exudative Age-related Macular Degeneration
Aqueous flare is increased in different kind of inflammations of eye. This is caused by disruption of blood-aqueous-barrier. The investigators assume that low grade systemic inflammation, such as periodontitis, increase aqueous…
- Trial name
- FLAREPARO (NCT03958461)
- Testing
- Anti-infective treatment of periodontal pockets
- Where
- Finland
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Helsinki
Age Related Macular Degeneration, Pigment Epithelial Detachment
On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)
The purpose of this study is to evaluate the efficacy and safety of intravitreal aflibercept injection in a population of neovascular AMD patients that have been previously treated with 2.0 mg ranibizumab for persistent PEDs.
- Trial name
- ROLL (NCT01670162)
- Testing
- Aflibercept
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Tennessee Retina
Nonexudative Age Related Macular Degeneration
Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration
This is a Phase II/III vehicle controlled, double masked, single center study. A single eye of 60 individuals with mild to moderate nonexudative Age-Related Macular Degeneration (AMD) will be randomly assigned to receive either…
- Trial name
- NCT01601483
- Testing
- MC-1101, MC-1101 Vehicle
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- MacuCLEAR, Inc.
Glaucoma, Diabetic Retinopathy (DR)
"My Eyes, My Light": Amar Chokh, Amar Alo
Eye disease affects 2.2 billion people globally, which in turn adversely affects schooling, economic productivity, and participation in social life.
- Conditions
- Glaucoma, Diabetic Retinopathy (DR), Hypertensive Retinopathy, Cataract
- Trial name
- ACA2 (NCT07135570)
- Testing
- Multimodal Screening for Eye Disease, cataract surgery
- Where
- Bangladesh
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Data Yakka, Inc.
Polypoidal Choroidal Vasculopathy (PCV), Age Related Macular Degeneration
Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy
To evaluate the Efficacy of a personalized treat-and-extend regimen of faricimab for treatment-naive polypoidal choroidal vasculopathy
- Trial name
- HANGANG (NCT07461441)
- Testing
- Faricimab Injection [Vabysmo]
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Yeungnam University College of Medicine
Age-Related Macular Degeneration
Study Of Combined VISUDYNE Therapy With Kenalog In CNV Secondary To Age-Related Macular Degeneration
To determine whether VISUDYNE therapy in combination with 4 mg intravitreal triamcinolone will reduce the average loss from baseline of best corrected visual acuity (BCVA) as compared with Visudyne therapy without intravitreal…
- Trial name
- NCT00140803
- Testing
- Visudyne, Kenalog
- Where
- 2 sites in United States, Canada
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Manhattan Eye, Ear & Throat Hospital
Neovascular Age-related Macular Degeneration
Blood Coagulation Parameters in Patients Receiving Intravitreal Aflibercept for Age-related Macular Degeneration
This study aims to evaluate coagulation parameters in treatment naive patients with neovascular age-related macular degeneration (AMD).
- Trial name
- NCT03509623
- Testing
- Blood sampling through direct peripheral venous puncture
- Where
- Greece
- Volunteers
- 47 people
- Sponsor
- University Hospital of Patras
Age Related Macular Degeneration
Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study
The Ranibizumab in Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration (RIP) Study is a prospective, multicenter, uncontrolled, interventional phase 2 clinical trial that investigates the effect of fixed…
- Trial name
- RIP (NCT01914159)
- Testing
- Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany)
- Where
- 3 sites in Germany
- Volunteers
- 24 people
- Sponsor
- University Hospital, Bonn
Intermediate Age-Related Macular Degeneration With Reticular Pseudodrusen
Lutein Iontophoresis in Intermediate AMD and Reticular Pseudodrusen - a Retrospective Study
There is limited data available on the efficacy and safety of Transscleral Lutein Iontophoresis (TSLI) in patients with in-termediate age-related macular degeneration (iAMD) and reticular pseudodrusen (RPD).
- Trial name
- NCT07420361
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Mario Damiano Toro
Age Related Macular Degeneration, Choroidal Neovascularization
Comparison Between Home Macular Perimeter and Optical Coherence Tomography (OCT) Visual Field Defects in Patients With Choroidal Neovascularization (CNV)
The FORESEE HOME is intended for the early detection of central and paracentral irregularities (abnormalities) in the visual field, most commonly associated with Age Related Macular Degeneration (AMD).
- Trial name
- NCT01336907
- Where
- France
- Sponsor
- Notal Vision Ltd.
Age-Related Macular Degeneration
Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections
This clinical study was designed to compare the safety and efficacy of brolucizumab 6 mg dosed every 4 weeks to aflibercept 2 mg dosed every 4 weeks in those neovascular age-related macular degeneration (nAMD) patients with…
- Trial name
- MERLIN (NCT03710564)
- Testing
- Brolucizumab, Aflibercept
- Where
- 61 sites in United States, Puerto Rico
- Volunteers
- 535 people
- Sponsor
- Novartis Pharmaceuticals
Exudative Age-related Macular Degeneration
Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration
Recently studies have shown that intravitreal injection of ranibizumab is effective for age related macular degeneration. However there are problems about injection regimen of maintenance phase.
- Trial name
- NCT02328209
- Testing
- ranibizumab
- Where
- Japan
- Volunteers
- 50 people
- Sponsor
- Mie University
Exudative Age-related Macular Degeneration
Ethical Issues of Using Gene Therapy in the Treatment of AMD
The objective of this study is to examine the legitimacy of gene therapy use in the treatment of exudative age-related macular degeneration (AMD).
- Trial name
- NCT07004361
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Nantes University Hospital
Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
The study will compare the safety of ophthalmic bevacizumab in vials versus pre-filled syringes in subjects diagnosed with a retinal condition that would benefit from treatment with intravitreal injection of bevacizumab…
- Conditions
- Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion
- Trial name
- NORSE SEVEN (NCT05112861)
- Testing
- bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Outlook Therapeutics, Inc.
Age-Related Macular Degeneration
Preparation of Patient Autologous Induced Pluripotent Stem Cell-derived Retinal Cells for AMD
This project intends to collect participant somatic cells to prepare autologous induced pluripotent stem cell-derived retinal cells for future cell therapy of age-related macular degeneration patient.
- Trial name
- NCT05991986
- Testing
- somatic cell collection
- Volunteers
- 10 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Glaucoma, Age-Related Macular Degeneration
Detecting Eye Diseases Via Hybrid Deep Learning Algorithms From Fundus Images
Eye health is of great importance for quality of life. Some eye diseases can progress and cause permanent damage up to vision loss if they are not treated early.
- Conditions
- Glaucoma, Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Retinopathy
- Trial name
- NCT06213896
- Testing
- Mydriatic Agent, Color Fundus Photography, EyeCheckup v2.0
- Where
- Turkey (Türkiye)
- Volunteers
- 1,528 people, healthy volunteers welcome
- Sponsor
- Ural Telekomunikasyon Sanayi Ticaret Anonim Sirketi
Neovascular Age-related Macular Degeneration
A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD
The study is designed for multi-center,randomized,double-masked,active-contralled study to evaluate effective and security of intravitreal injection of IBI302 in subjects with neovascular age-related macular degeneration.
- Trial name
- NCT05972473
- Testing
- Aflibercept Ophthalmic, IBI302
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Geographic Atrophy, Age-related Macular Degeneration
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
The main purpose of this study is to assess the ocular and systemic safety and tolerability of RO7669330 in participants with GA secondary to AMD in at least one eye in Part 1, or both eyes in Part 2, after multiple unilateral…
- Trial name
- NCT06961370
- Testing
- RO7669330, Syfovre™, Izervay™
- Where
- 17 sites in United States
- Volunteers
- 27 people
- Sponsor
- Hoffmann-La Roche
Exudative Age-related Macular Degeneration
Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative Age-Related Macular Degeneration
Over the last several years, the standard of care for wet macular degeneration has become treatment with intravitreal injections of ranibizumab (Lucentis, Genentech), administered as frequently as every 4 weeks.
- Trial name
- NCT01526070
- Testing
- Intravitreal injection of Aflibercept
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- Stanford University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.